TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma

TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma

Osteosarcoma is the most common malignant bone tumor in adolescence and childhood. Metastatic osteosarcoma has a poor prognosis with an overall 5‐year survival rate of approximately 20%. TAS‐115 is a novel multiple receptor tyrosine kinase inhibitor that is currently undergoing clinical trials. Usin...

Full description

Bibliographic Details
Main Authors: Naohiro Yasuda, Satoshi Takenaka, Sho Nakai, Takaaki Nakai, Shutaro Yamada, Yoshinori Imura, Hidetatsu Outani, Kenichiro Hamada, Hideki Yoshikawa, Norifumi Naka
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:FEBS Open Bio
Subjects:
LM8
lung metastasis
molecular targeted therapy
osteosarcoma
TAS‐115
Online Access:https://doi.org/10.1002/2211-5463.12827

Internet

https://doi.org/10.1002/2211-5463.12827

Similar Items